Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes ·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing...

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...